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The outcomes of patients with metastatic/inoperable gastrointestinal 
stromal tumors (GIST) treated with imatinib 
– an interim multicenter analysis of Polish Clinical GIST Registry
W∏odzimierz Ruka1, Piotr Rutkowski1, Zbigniew Nowecki1, 
Czes∏aw Osuch2, El˝bieta Staros∏awska3, Andrzej Rozmiarek4, Marek Krawczyk5, 
Pawe∏ Nyckowski5, Maria B∏asiƒska-Morawiec6, Agnieszka Jagie∏∏o-Gruszfeld7, 
Stanis∏aw Góêdê8, Anna Nasierowska-Guttmejer9, Urszula Grzesiakowska10, 
Beata Utracka-Hutka11, Wanda Michej9
T h e  a i m.  of the study was to analyze the clinical outcomes of imatinib treatment in inoperable/metastatic gastrointestinal
stromal tumors (GIST) CD 117(+) in Polish institutions collaborating in the Clinical GIST Registry.
M a t e r i a l  a n d  m e t h o d s.  Complete basic demographic and clinical data was available in 165 advanced
(inoperable/metastatic – M1) patients treated with imatinib in a dose of 400-800 mg (155 patients for survival analysis) between
09/2001 and 01/2005 and registered in the Clinical GIST Registry in Warsaw. This data was compared with that of 107 patients
without evidence of recurrent disease (M0) followed-up at the M. Sklodowska-Curie Memorial Cancer Center – Institute of
Oncology in Warsaw.
R e s u l t s.  We observed the prevalence of male patients in the M1 group as compared to M0 patients (p=0.001). We found
significantly higher median tumor size (11 cm) and median mitotic count value (10/50 HPF) in M1 patients as compared to
the M0 group (5.5 cm and 2/50HPF, respectively) [p<0.001]. The percentage of gastric location (together with the lower
esophagus and duodenum) was significantly lower in the M1 group than in the M0 group, 36% and 61% respectively
(p=0.01). In the group of 155 patients treated with imatinib due to inoperable/metastatic lesions, 141 (91%) were alive at the
time of the last evaluation in 01/2005. Ten patients (6.5%) demonstrated complete remission of disease and the other 102 pts
(66%) remained on imatinib treatment and have maintained disease with partial response (40%) or stabilization (26%) only
according to RECIST criteria. The estimated 3-year overall and progression-free survival was 75% and 64.5%, respectively.
C o n c l u s i o n s.  It has been shown that it was possible to achieve a satisfactory clinical outcome in patients with such a rare
malignancy as GIST treated with new molecular targeted therapy in different regional cancer centers in Poland. Direct
multidisciplinary collaboration between specialists caring for patients with GIST in Poland has shown and confirmed the
outstanding role of the Polish Clinical GIST Registry.
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Introduction
In August 2001 the EORTC trial No. 62005 at the
Institute of Oncology in Warsaw for the recruitment of
patients with inoperable/metastatic gastrointestinal
stromal tumors (GIST) with positive immunostaining
for c-KIT (CD117) was opened. At that time the trial
was the third in the world (and the first conducted in
Poland) – a prospective, randomized study evaluating the
efficacy of molecular targeted treatment of GIST with
small-molecule tyrosinase kinase inhibitor – imatinibe
mesylate. Patient recruitment was finished in February
2002. The preliminary results of the study were published
during the Annual Society of Clinical Oncology Annual
Meetings 2003 and 2004, and finally were published in
2004 [1]. Soon after entering first patients we had realized
that the treatment of GIST patients is an effort of many
specialists throughout Poland: pathologists, surgeons,
oncologists and radiologists. To strike up closure
cooperation, the Polish Clinical GIST Registry was
organised in 2002 as a multidisciplinary forum for
exchanging information about GIST treatment and
research. It holds national meetings twice a year in
different centers in Poland. The main points of interest of
the Clinical GIST Registry are: propagation of knowledge
about GIST (diagnosis/treatment); clinical data collection,
analysis of treatment outcomes, analysis of co-existence of
other neoplasms in GIST patients, the evaluation of the
role of surgery after imatinib treatment and co-operation
in clinical trials and molecular research. The main
achievement of our Registry is the extension of awareness
of the GIST disease among doctors and the increase of
newly diagnosed cases of GIST in Poland, as well as the
implementation of new, effective treatment of this
malignancy, as is the case in other European countries.
The aim of this study is to analyze the clinical outcomes of
imatinib treatment in inoperable/metastatic GIST CD
117(+) in Polish centers collaborating in the Clinical
GIST Registry.
Material and method
We have collected data related to inoperable and/or metastatic
GIST patients treated with imatinib from all institutions
participating in the Clinical GIST Registry – oncological
centers throughout Poland – at the beginning of January
2005. The information was obtained from the centers with
the aid of a special questionnaire published on the web page
(http://www.coi.waw.pl) and sent by e-mail (gist@coi.waw.pl)
or fax. There were 98 patients treated at the Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology
(CCIO) in Warsaw and 103 patients in other Polish centers.
Complete basic demographic and clinical data was available in
case of 165 advanced patients treated with imatinib and
registered in the Clinical GIST Registry in Warsaw. These data
were compared with that of 107 patients without evidence of
recurrent disease followed-up in the CCIO in Warsaw (Table I).
The criteria of eligibility for imatinib treatment were as
follows:
– histological diagnosis of GIST,
– c-Kit (CD117) positive staining (Dako polyclonal antibodies),
– metastatic and/or inoperable lesions,
– measurable disease on computed tomography scans,
– WHO performance status ≤3,
– no concomitant therapy for disease,
– adequate renal and liver function.
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Prze˝ycia chorych na rozsiany i nieoperacyjny GIST leczonych imatinibem 
– analiza etapowa Klinicznego Rejestru GIST
C e l e m  badania by∏a analiza wyników leczenia chorych na nieoperacyjny/rozsiany nowotwór podÊcieliskowy przewodu
pokarmowego (GIST) CD 117(+), leczonych imatinibem w polskich oÊrodkach wspó∏pracujàcych w Rejestrze Klinicznym
GIST.
M a t e r i a ∏  i m e t o d y.  Kompletne podstawowe dane demograficzne i kliniczne uzyskano u 165 chorych z zaawansowanym
GIST (nieoperacyjnym/rozsianym – M1), leczonych imatinibem w dawce 400-800 mg (155 chorych poddano analizie
prze˝ycia) w okresie 09/2001 – 01/2005 i w∏àczonych do Rejestru Klinicznego GIST w Warszawie. Dane te porównano ze 107
chorymi bez cech nawrotu choroby (M0), poddanych obserwacji w Centrum Onkologii – Instytucie w Warszawie.
W y n i k i.  Obserwowano przewag´ p∏ci m´skiej w grupie M1 w porównaniu z M0 (p=0,001). Stwierdzono istotnie wi´kszà
median´ wielkoÊci guza (11 cm) i indeksu mitotycznego (10/50 HPF) u chorych w stopniu M1 ni˝ u chorych w grupie M0
(odpowiednio: 5,5 cm i 2/50 HPF) [p<0,001]. Odsetek chorych na GIST, których pierwotny guz umiejscowiony by∏ w ˝o∏àdku
(∏àcznie z dolnym odcinkiem prze∏yku i dwunastnicà), by∏ znaczàco mniejszy w grupie M1 ni˝ M0 (odpowiednio: 36 i 61%;
p=0,01). W grupie 155 chorych leczonych imatinibem z powodu rozsianych/nieoperacyjnych zmian 141 (91%) ˝y∏o
w 01/2005. U 10 chorych (6,5%) obserwowano ca∏kowità odpowiedê na leczenie, a dalszych 102 (66%) by∏o leczonych
imatinibem po uzyskaniu cz´Êciowej remisji (40%) lub stabilizacji (26%) choroby zgodnie z kryteriami RECIST. Oszacowane
3-letnie prze˝ycia ca∏kowite i wolne od progresji choroby wynios∏y odpowiednio 75% i 64,5%.
W n i o s k i.  Wykazano, ˝e mo˝liwe jest uzyskanie satysfakcjonujàcych klinicznych wyników leczenia chorych z tak rzadkim
nowotworem, jak GIST za pomocà nowoczesnej terapii celowanej molekularnie w ró˝nych regionalnych oÊrodkach
onkologicznych w Polsce. Âcis∏a wielodyscyplinarna wspó∏praca specjalistów zajmujàcych si´ chorym na GIST w Polsce
potwierdzi∏a istotnà rol´ Rejestru Klinicznego GIST.
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Imatinib treatment started from the dose of 400 mg once
daily orally. The response to treatment was evaluated according
to the RECIST criteria with computed tomography imaging
examinations performed every 2-3 months. In case of progres-
sion the dose was increased to 600-800 mg daily. In case of
further progression imatinib treatment was stopped. The
imatinib dose was reduced to 300 mg daily due to recurrent
grade 3 toxicity (neutropenia) in 2 cases.
For statistical computations the contingency tables were
analyzed by the chi-square test. Groups were compared for age
differences using the t-test for normal distribution of parameters
and for other parameters, with non-normal distribution the
Mann-Whitney U-test was used. Differences were considered
statistically significant if p-values were <0.05. The Kaplan-Meier
method was used for the analysis of survival curves. Overall
survival (OS) and progression-free survival (PFS) time were
calculated from the date of start of imatinib treatment to the
date of the most recent follow-up, progression or death (for
PFS and OS, respectively). 14 patients were excluded from the
survival analysis because of the lack of detailed dates of the
start of imatinib treatment. We excluded further 32 patients
because of a too short follow-up time (minimal follow-up time
necessary for the evaluation of the results of treatment was 6
months, which means that imatinib treatment should have been
started before June 31st, 2004). Finally, for the survival analysis,
we included 155 GIST patients treated with imatinib from
09/2001 to 01/2005. Median follow-up time was 17.7 months for
survivors and mean follow-up time – 19 months. For data
collection the hospital information system ONCOsys and the
Clinical GIST Registry databases were used.
Results
The characteristics of the group of c-KIT positive GIST
patients with inoperable/metastatic lesions treated with
imatinib (group M1) and patients followed-up without
evidence of recurrent disease after radical operation
(group M0) are shown in Table I. Median age in the M1
group was 56 years and in the M0 group – 60 years
(p=0.2). Men comprised the majority of patients in the
inoperable/metastatic group, but, on the contrary, women
predominated among patients without recurrence of
disease after primary surgery (p=0.001).
The median tumor size (11 cm) was significantly
higher in the M1 group as compared to the M0 group
(5.5 cm) [p<0.001]. Similarly, the median mitotic count
value was significantly higher in the M1 group
(10/50HPF) than in the M0 group (2/50HPF) [p<0.001].
The characteristics of GIST locations were different
in the M1 and M0 groups. The percentage of gastric
locations (together with the lower esophagus and
duodenum) was clearly lower in the M1 group than in
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Table I. Patient characteristics (groups: M1 – patients with inoperable/metastastatic GIST lesions treated with imatinib; 
M0 – patients without evidence of disease, follow-up only)
Clinicopathological feature M1 M0 Total p-value
165 pts 107 pts 272 pts
Age [years] Range 17-83 years 23-85 years 17-85 years
Mean 56 years 58 years 57 years
Median 56 years 60 years 58 years n.s.
Gender Female 69 (41.8%) 66 (61.6%) 135 (49.6%)
Male 96 (52.8%) 41 (38.4%) 137 (50.4%) p=0.001
Primary tumor site Esophagus 2 (1%) 2 (0.7%)
Stomach 50 (30%) 58 (54%) 108 (39.7%)
Duodenum 8 (5%) 7 (7%) 15 (5.5%)
Small bowel 60 (36%) 34 (31%) 94 (34.6%)
Large bowel/rectum 12 (7%) 2 (2%) 14 (5.1%)
Retroperitoneal space 14 (9%) 2 (2%) 16 (5.9%)
Others, intraperitoneally with 
Unknown primary origin 19 (12%) 4 (4%) 23 (8.5%) p<0.001
Tumor size [cm] 104 pts 80 pts
Mean 13 cm 7 cm
Median 11 cm 5.5 cm p<0.001
Mitoses number in 50 High Power Fields 48 pts 44 pts
Median 10 2 p<0.001
Time to recurrence after primary 
operation R0/R1 96 pts
Range 1 – 182
Mean 24 months
Median 13 months
Follow-up time 104 pts
Range 1 – 132
Mean 18 months
Median 12 months
Pts = patients
the M0 group, 36% and 61% respectively. On the
contrary, the percentage of bowel GIST locations (small
and large together) is significantly higher in the M1 group
as compared to the M0 group, 43% and 33% respectively
(p=0.01).
The median time to GIST recurrence was 13 months
in the M1 group and was comparable to the median time
of 12 months of follow-up in the M0 group. It means that
the lack of recurrence in the M0 group was not related to,
or caused by, the shorter time of follow-up only (Table I).
We have also observed a relatively high ratio of
a second co-existent malignant neoplasm (8.1%) in the
past history of GIST patients (8.5% – 14/165 in M1 and
7.5% – 8/107 in M0 groups).
In the group of patients with inoperable/metastatic
lesions (M1) only two cases of dissemination outside the
abdominal cavity (one to the bones and one to the lungs)
were found. All patients in this group have had liver
metasteses or intraperitoneal dissemination and,
sometimes, inoperable local recurrences or primary
tumors (data not shown).
In the eligible for analysis group of 155 patients
treated with imatinib due to inoperable/metastatic lesions,
141 (91%) were alive at the time of the last evaluation
in January 2005. Ten patients (6.5%) demonstrated
complete remission of disease and the other 102 pts
(66%) remained on imatinib treatment and have main-
tained disease with partial response (40%) or stabilization
(26%) only according to RECIST criteria. Disease
progression was observed in 27.5% of patients. Detailed
results of imatinib treatment are presented in Table II.
Nineteen patients underwent adjuvant radical surgery
after partial/complete response obtained during imatinib
treatment. The estimated 3-year overall and progression-
free survival were 75% and 64.5%, respectively (Figure 1).
The adverse events were rather frequent during
imatinib treatment, but most of them were mild (grade 
1-2). The most common were: fluid retention, edema,
nausea, abdominal and muscle pain, diarrhea and anemia.
We observed some cases of grade 3-4 toxicity: neutropenia
(4 cases), ascites (2 cases), skin rash (2 cases), tumor
hemorrhage requiring surgery (1 case) and soft tissue
infection in 2 cases (data not shown).
Discussion
Gastrointestinal stromal tumors (GIST) comprise a re-
cently defined entity of the most common mesenchymal
neoplasms of the abdominal cavity. GIST is thought to
arise from precursors shared with the normal interstitial
cells of Cajal – the gut pacemaker cells. They are charac-
terized by overexpression of mutated c-KIT receptor
detected by CD117 immunostaining [2, 3]. The intro-
duction of molecular targeted therapy with imatinib
mesilate has focused attention on GIST patients [4-7].
The current study presents the first multicenter results
of treatment of inoperable/metastatic GIST patients in
Poland.
GISTs occur in both genders with a more or less
similar frequency, but among patients with inopera-
ble/metastatic disease we observed male predominance.
The median age of patients was 55-60 years but,
unexpectedly, patients with inoperable/metastatic GIST
were slightly younger than those without disease
recurrence after radical primary surgery. The tumor size
and the mitotic count, considered to be the most
important prognostic factors, were significantly higher in
the metastatic/inoperable group as compared to the non-
recurrent group. This “advanced patients” group also
comprised a lower percentage of gastric GISTs, which
are considered to possess a lower recurrence potential
[3, 8]. In general, all the listed clinical and pathological
factors could play a crucial role in GIST prognostification
(Table III). Undoubtedly, the quality of GIST surgery
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OS 75%
PFS 64,5%
Time [months]
1
0,8
0,6
0,4
0,2
0
0 3 6 9 12 15 18 21 24 27 30 33 36
Figure. 1. Overall (OS) and progression-free (PFS) survival of patients
treated with imatinib
Table III. Probable prognostic factors in GIST patients
Parameter Category .
tumor size ≤5 cm vs. >5 cm
mitotic rate ≤5/HPF vs. >5/HPF
tumor location stomach vs. other
gender female vs. male
age (as continuous variable) older vs. younger 
mutation type KIT (exon 11,9, other, WT) vs. PDGFR
type of surgery R0 vs R1
HPF – high power field; WT – wild type; PDGFR – Platelet-derived
growth factor receptor
Table II. The evaluation of response to imatinib treatment in 155
GIST patients (median follow-up 17.7 months)
Result No of patients %
Complete remission (CR) 10 6.5%
Partial remission (PR) 62 40.0%
Stable disease (SD) 40 26.0%
Progressive disease (PD) 43 27.5% 
should also play a crucial role in GIST patients prognosis
[9].
The incidence of the registered advanced and
aggressive (inoperable/metastatic) cases in Poland may
be estimated at approx. 3 new cases per million annually,
which means that according to statistics 1 case per
a million of inhabitants per year is still not registered.
The reliable data on the incidence of GIST are still not
fully available, but the real number of all GIST cases in
many countries is underestimated [8, 10, 11].
Imatinib mesylate therapy is the first and only one
effective nonsurgical treatment for GIST. Imatinib
mesylate prevents kinase signaling by blocking (in GIST)
the KIT-associated signaling cascade. Several clinical trials
have now been conducted to confirm the dramatic
efficacy of imatinib in the treatment of GIST in a majority
of patients with inoperable/metastatic disease [4, 6, 10].
When compared to historical clinical data, in which the
median survival of those patients was 10-12 months, the
method is really superior (in our group of patients
the median survival has not been reached after a median
follow-up time of almost 18 months and the estimated
3-year progression-free survival was 64.5%). However,
imatinib is not a panaceum for GIST patients – with
a longer follow-up time the rate of patients who have
progressive or are resistant to imatinib increases and
complete remission is rare (<10%). This implies
the necessity for further studies on new drugs in
resistant cases (SU11248 and AMG 706 are currently
evaluated in the clinical setting) and, what is more
important, on the combination of imatinib therapy with
surgery [10].
The most effective method of response evaluation is
computed tomography imaging, but the criteria of
response are rather controversial and unsatisfactory and
should be reconsidered [1].
The role of imatinib therapy in the adjuvant and
neoadjuvant setting has not yet been established and is
being evaluated in clinical trials (ACOSOG Z900 and
Z9001; RTOG 0132 and EORTC 62024). The optimal
dose for this orally administered, well-tolerated agent is
still under discussion. There are some arguments that
dose dependency (400 mg vs 800 mg) of the response to
imatinib is related to the mutational status of the tumors
and their localization (stomach vs small bowel) [12]. In
patients with disseminated bowel GIST not responding to
the 400 mg dose it appears to be justified to administer
800 mg daily doses.
In our paper it has been shown that it is possible to
achieve a satisfactory clinical outcome in patients with
such a rare malignancy as GIST treated with new
molecular targeted therapy in different regional cancer
centers in Poland. Direct multidisciplinary collaboration
between specialists caring for patients with GIST in
Poland has shown and confirmed the outstanding role of
the Polish Clinical GIST Registry.
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